Prematurely closed phase II RCT in 111 patients with advanced neuroendocrine tumours: adding capecitabine to 177Lu-Dotatate did not improve objective response (32% vs 46%, P=0.348), median PFS or median OS vs 177Lu-Dotatate alone, and was associated with lower QALYs.
RCTn = 111 patients
Becx et al. A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors